Pfizer found to be 100% effective in children aged between 12-15

The Pfizer Covid vaccine has been found to be 100% effective at preventing serious illness in 12 to 15 year olds.

Pfizer revealed the sunning results in a statement following mass testing of the vaccine on children within that age group.

Covid-19 vaccines are currently being rolled out across the world, mostly targeting the older and most vulnerable population who are most at disk of serious complications and death should they contract the virus.

The Pfizer Covid vaccine has been found to be 100% effective at preventing serious illness in 12 to 15 year olds. (REUTERS)

In Scotland and the rest of the UK those most at risk have been prioritised.

Pfizer's vaccine, also referred to as the Pfizer-BioNTech jab, has been authorised for over 16s in the USA but has yet to be administered en masse to younger people, as more trial results were gathered, reports The Mirror.

However in a study of 2,260 US volunteers aged 12 to 15, preliminary data showed no cases of Covid-19 among fully vaccinated adolescents, compared with 18 among those given placebo shots, Pfizer said in a statement this morning.

The Pfizer Covid vaccine has been found to be 100% effective at preventing serious illness in 12 to 15 year olds. (Getty Images)

Albert Bourla, Chairman and Chief Executive Officer of Pfizer said: "We share the urgency to expand the authorisation of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15.

“We plan to submit these data to FDA as a proposed amendment to our Emergency Use Authorization in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year.”

Researchers reported high levels of virus-fighting antibodies in those children who were vaccinated in the trial. -which was higher than in studies of young adults.

According to Pfizer the vaccinated children had side effects similar to those suffered by young adults given the jab, such as arm pain, chills and tiredness.

Pfizer and its German partner BioNTech in coming weeks plan to ask the US Food and Drug Administration and European regulators to allow emergency use of the vaccine starting at the age of 12.

Last week, the companies gave the first vaccine doses in a series of trials testing the vaccine in younger children, that will eventually go to those as young as 6 months of age.